A Hong Hong-based developer has accused HWL Ebsworth of failing to advise that by using a foreign-domiciled vehicle to purchase a share in a lender that provided mortgages to overseas buyers in two of Melbourne’s biggest developments it would subject the mortgages to Foreign Investment Review Board review.
The first ever amicus appointed in a fight over the wording of an opt out notice in a class action has told a court a proposed novel funding model in a case against retirement home provider Aveo Group could be a “nightmare scenario” for certain group members.
Norton Rose Fulbright has been hit with two negligence suits in a week blaming the law firm for botched property sales in Victoria six years ago.
A judge has declined to pass on a senior barrister’s $18,000 cancellation fee as part of an adverse costs order for a vacated trial, noting that such fees are not standard or common practice.
Ambulance Victoria is being sued by a former executive who claims she was not treated the same as her male colleagues and was subject to “disrespectful, undermining” conduct from senior colleagues.
The Full Federal Court has dismissed former Blue Star Helium CEO James Cruickshank’s challenge to a $40,000 penalty and four-year ban for failing to disclose to shareholders the identity of the buyer behind a botched sale of Texas oil assets.
A Melbourne-based investment management group is refusing to vacate two rooms forming part of a managed investment scheme at the Yarra Valley Lodge Hotel, according to a lawsuit filed by the Australian and Pacific Investment Corporation.
A judge has ordered Pacific National to hand over safety management system documents in a privilege fight over a deadly 2019 train crash, observing large organisations often bring on lawyers for a privilege “shield”.
A judge has cautioned senior barrister Sue Chrysanthou over her colourful description of a 60 Minutes episode at the heart of Euro Pacific Bank boss Peter Schiff’s defamation case against Nine, urging the silk to “be careful”.
Samsung Bioepis Australia has sued fellow biotechnology company Fresenius Kabi over a biosimilar of top selling immunosuppressant drug Humira, saying the invention ‘does not achieve the promise’ of a better formulation using fewer ingredients.